In vitro activity of new beta-lactam antibiotics and other antimicrobial drugs against anaerobic isolates from obstetric and gynecological infections

Inadequate levels of metronidazole in subcutaneous fat after standard prophylaxis

The efficacy of antibiotic prophylaxis depends on appropriate tissue levels of the drug being present at the time of potential wound contamination. Metronidazole concentrations in serum, muscle and subcutaneous fat were measured after a single intravenous dose given at two different intervals before operation. Twenty-six patients undergoing abdominal wall procedures were divided into two groups. Patients in group 1 received metronidazole 500 mg intravenously 2 h before surgery, and those in group 2 were given the drug during induction of anaesthesia. Mean plasma levels of metronidazole at the beginning of the procedure were significantly lower (P = 0.01) in group 1 (7.3 (95 per cent confidence interval 5.7-8.9)) micrograms/ml than in group 2 (12.3 (8.9-15.7)) micrograms/ml although in both cases were above the minimum inhibitory concentration for 90 per cent of Bacteroides fragilis. Similar therapeutic concentrations of metronidazole were achieved in plasma and muscle in both groups at the end of the operation. However, patients in both groups had non-therapeutic concentrations of metronidazole in subcutaneous fat: group 1 0.9 (0.6-1.2) micrograms/mg, group 2 1.2 (0.7-1.7) micrograms/mg at the beginning of operation, and 1.2 (0.8-1.6) and 1.5 (0.9-2.1) micrograms/mg respectively at the end of the procedure. It is concluded that infusion of metronidazole 2 h before surgery or during induction of anaesthesia achieved adequate plasma and muscle levels but failed to achieve therapeutic levels in subcutaneous fat.

Quality control guidelines for testing cefotetan in the reference agar dilution procedure for susceptibility testing of anaerobic bacteria

Reference values for quality control of in vitro susceptibility tests with cefotetan against anaerobic bacteria were determined in two independent multilaboratory studies with the approved National Committee for Clinical Laboratory Standards agar dilution method and three control strains (Bacteroides fragilis ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741, and Clostridium perfringens ATCC 13124). The results of the two studies were in agreement. The recommended MIC control limits for B. fragilis ATCC 25285 and B. thetaiotaomicron ATCC 29741 are 4.0 to 16 micrograms/ml and 32 to 128 micrograms/ml, respectively. MICs for C. perfringens ATCC 13124 were too variable to be useful for controlling tests with cefotetan.

Recovery of anaerobic bacteria from clinical specimens in 12 years at two military hospitals

Examination of 15,844 clinical specimens submitted over 12 years (1973 to 1985) to the anaerobic microbiology laboratories in two military hospitals demonstrated the recovery of anaerobic bacteria in 4,458 (28.1%) specimens. The specimens yielded 6,557 anaerobic isolates (1.47 isolates per specimen). Bacteroides spp. accounted for 43% of all isolates; anaerobic gram-positive cocci, 26%; Clostridium spp., 7%; and Fusobacterium spp., 4%. Bacteroides spp. predominated in abscesses, obstetrical and gynecological (OBG) infections, abdominal infections, cysts, wounds, and tumors. Members of the Bacteroides fragilis group accounted for 44% of all Bacteroides spp., and of them, B. fragilis was mostly isolated in abscesses, wounds, abdomen, and blood. Pigmented Bacteroides spp. accounted for 21% of all Bacteroides sp. isolates and were mostly isolated in sinus, eye, chest, bone, and ear infections. Bacteroides melaninogenicus accounted for 42% of this group's isolates. Bacteroides bivius accounted for 9% of Bacteroides spp., and most isolates were found in OBG infections. Anaerobic gram-positive cocci were mostly isolated in OBG infections, abscesses, and wounds. The predominant anaerobic gram-positive cocci were Peptostreptococcus magnus (18%), Peptostreptococcus asaccharolyticus (17%), Peptostreptococcus anaerobius (16%), and Peptostreptococcus prevotii (13%). Clostridium spp. were mostly isolated from wounds, abscesses, abdominal infections, and blood. The predominant strain was Clostridium perfringens (48%). Fusobacterium spp. were recovered in abscesses and abdominal and OBG infections. The predominant isolate was Fusobacterium nucleatum (47%). These data illustrate the relative frequency of the different anaerobic bacteria in a variety of infections and demonstrate the predominance of certain isolates at different sites.

Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy

Imipenem is the first available semisynthetic thienamycin and is administered intravenously in combination with cilastatin, a renal dipeptidase inhibitor that increases urinary excretion of active drug. In vitro studies have demonstrated that imipenem has an extremely wide spectrum of antibacterial activity against Gram-negative and Gram-positive aerobic and anaerobic bacteria, even against many multiresistant strains of bacteria. It is very potent against species which elaborate beta-lactamases. Imipenem in combination with equal doses of cilastatin has been shown to be generally well tolerated and an effective antimicrobial for the treatment of infections of various body systems. It is likely to be most valuable as empirical treatment of mixed aerobic and anaerobic infections, bacteraemia in non-neutropenic patients and serious hospital-acquired infections.

Microbiology of the female genital tract

Patients who contract genital tract infections are predominantly young, are otherwise healthy, and generally respond well to treatment for bacterial infections. These infections are most commonly polymicrobial in etiology, with several noteworthy exceptions. Often there is an inciting event such as childbirth, surgical intervention, pregnancy termination or intrauterine contraceptive device insertion. With treatment, prognosis for cure is excellent; however, sequelae such as recurrent infections, infertility, or ectopic pregnancy can be serious. Bacteria encountered in the female genital tract can be divided into aerobic and anaerobic organisms. Among the aerobic gram-positive organisms, several varieties of streptococci such as Group B streptococci and enterococci occur frequently. Staphylococcus aureus is an infrequent but important pathogen. Among the aerobic gram-negative organisms, the most common is Escherichia coli. Klebsiella sp. and Proteus sp. occur in about 5% of genital tract infections. Species that are more resistant to antibiotics, such as Pseudomonas aeruginosa and Enterobacter sp., occur in approximately 1% or 2% of these cases and are more likely to appear in patients who have previously received antibiotic therapy or who have been hospitalized for some time. Among the anaerobic organisms, the most common gram-positive isolates are Peptostreptococci and Peptococci. Clostridia sp. occurs less frequently. Among the anaerobic gram-negative organisms, the Bacteroides sp. most frequently encountered are Bacteroides bivius and Bacteroides disiens. Bacteroides fragilis is still a common problem but appears to be less predominant. Other organisms encountered are Chlamydia trachomatis, the genital mycoplasmas, yeasts, protozoa, and viruses.

Review of the in vitro spectrum of activity of imipenem

Imipenem (N-formimidoyl thienamycin, MK0787), a new carbapenem was found to have the widest antimicrobial activity of currently available beta-lactam drugs. Enterobacteriaceae had minimal inhibitory concentrations of imipenem of 8.0 micrograms/ml or less for 99.8 percent of clinical isolates. Only rare strains of Enterobacter species and Proteus mirabilis have higher imipenem minimal inhibitory concentration results. Hemophilus and Neisseria species were inhibited, but minimal inhibitory concentrations of imipenem were higher than those reported for third-generation cephalosporins. Only Pseudomonas maltophilia and Pseudomonas cepacia strains were imipenem resistant (MIC50 greater than 32 micrograms/ml) among the commonly isolated non-enteric gram-negative bacilli. All anaerobes were found susceptible to imipenem with the exception of some strains of Clostridium difficile. Staphylococcus species and non-enterococcal streptococci were very susceptible to imipenem. Streptococcus faecalis had higher minimal inhibitory concentrations of imipenem (MIC90 3.1 micrograms/ml) and S. faecium strains were frankly resistant. Methicillin-resistant S. aureus isolates had a MIC90 of 27.2 micrograms imipenem/ml. Imipenem was generally bactericidal except for marked minimal inhibitory and minimal bactericidal concentration differences with enterococci, Listeria, methicillin-resistant staphylococci, and some P. aeruginosa strains. The minimal inhibitory and minimal bactericidal concentrations of imipenem were not significantly influenced by organism inoculum size, probably because of its beta-lactamase stability to nearly all commonly encountered bacterial enzymes. Imipenem was found to be an excellent inhibitor of beta-lactamases and a potent enzyme inducer. The induction characteristic seems responsible for the antagonistic interactions of imipenem with some enzyme-labile beta-lactams in combination. Imipenem had limited stability in some in vitro susceptibility test systems. The 10 micrograms disk test or dry-form broth micro-dilution systems were preferred, applying the interpretive criteria from the National Committee for Clinical Laboratory Standards (M2-A3). Imipenem-resistant strains were rarely found in clinical practice and bacteria resistant to newer beta-lactams and aminoglycosides were generally very susceptible to this new carbapenem.

In vitro activity of cefbuperazone and other antimicrobial agents against isolates from the female genital tract

Cefbuperazone (BMY 25182), a new cephamycin, showed activity similar to those of moxalactam and other cephalosporin-cephamycins against aerobic and anaerobic bacteria from female genital tract infections. MICs of the antimicrobial agents were less than or equal to 16 micrograms/ml for greater than 97% of organisms tested. All of the anaerobic bacteria tested were susceptible to clindamycin, metronidazole, and chloramphenicol.

Clindamycin levels in reproductive tissues

Clindamycin is widely used in a variety of obstetric and gynecologic infections. Despite in vitro and clinical evidence of activity against anaerobes, genital organ tissue levels resulting from intravenous administration of the drug have not previously been reported. Following a single intravenous infusion of 600 mg of clindamycin phosphate, tissue levels were determined in operative specimens obtained from ten women. Specimens of cervix, uterus, fallopian tube, and ovary were obtained, and mean Clindamycin levels for each site were: cervix, 2.63 micrograms/ml; endometrium, 5.58 micrograms/ml; myometrium, 2.39 micrograms/ml; fallopian tube, 2.96 micrograms/ml; and ovary, 3.74 micrograms/ml. The mean serum level was 6.26 micrograms/ml at the time of uterine artery interruption. The clindamycin concentrations at all sites exceeded the usual therapeutic minimal inhibitory concentration, substantiating the usefulness of clindamycin in obstetric and gynecologic anaerobic infections.

Antimicrobial susceptibilities of anaerobic bacteria isolated from female genital tract infections

Certain species or subspecies of anaerobic bacteria are isolated with higher frequency from female genital tract infections than from other anatomic sites. To gain susceptibility data more specific to the treatment of these infections, nine antimicrobial agents were tested by an agar dilution technique against 230 anaerobic bacteria isolated solely from obstetric and gynecological infections. These genital isolates were, in general, very susceptible to imipenem (most active, inhibiting all gram-negative rods at less than or equal to 1 microgram/ml), clindamycin (all isolates inhibited at less than or equal to 4 micrograms/ml), metronidazole (all gram-negative rods inhibited at less than or equal to 4 micrograms/ml), and chloramphenicol. Penicillin G had generally low activity against Bacteroides spp., not restricted to just the Bacteroides fragilis group, although it was very active against gram-positive species. Bacteroides bivius, a species uniquely common in female genital infections, was particularly resistant (90% MIC, 64 U/ml). Also, the Bacteroides melaninogenicus isolates were less susceptible than previously reported for isolates not exclusively from genital sites. Compared with moxalactam, cefotaxime, and cefoperazone, cefoxitin usually demonstrated equal or greater activity against most Bacteroides spp., with the exception of greater activity of moxalactam against B. fragilis (formerly subsp. fragilis). Resistance to moxalactam was observed among strains of Peptostreptococcus anaerobius, a common genital isolate. Overall, the activities of these four drugs were not as predictable as those observed for clindamycin, metronidazole, chloramphenicol, and imipenem.

Role of Bacteroides bivius beta-lactamase in beta-lactam susceptibility

The susceptibility of 46 clinical isolates of Bacteroides bivius to amoxicillin, cefotaxime, cefoxitin, ceftizoxime, cephaloridine, cephalothin, moxalactam, penicillin G, amoxicillin plus clavulanic acid in a ratio of 2:1, carbenicillin, cefamandole, and ceftazidime was determined by an agar dilution technique. For the first eight agents susceptibility testing was also done with the addition of clavulanic acid (0.75 microgram/ml). For all agents, beta-lactamase-positive strains (35, using a nitrocefin slide test) were inhibited at higher concentrations than beta-lactamase-negative strains. Clavulanic acid reduced the susceptibility of the beta-lactamase-positive strains to the level of the beta-lactamase-negative strains to all agents. We prepared crude extracts of beta-lactamase from six strains. Activity against nitrocefin was directly related to their susceptibilities. The beta-lactamase had a mixed-substrate profile, hydrolyzing both penicillins and cephalosporins. Our results suggest a slow inactivation of cefoxitin, ceftizoxime, and moxalactam by the beta-lactamase. Clavulanic acid and cefoxitin inhibited the enzyme, whereas p-hydroxymercuribenzoate and cloxacillin did not. Thus, there was a clear relationship between beta-lactamase activity and susceptibility to beta-lactams, including cefoxitin and third-generation cephalosporins. The substrate and inhibition profiles of the B. bivius beta-lactamase were different from those of enzymes found in the "B. fragilis group."

In vitro activity of imipenem--a review

A review is given of the microbiological properties of imipenem, a new carbapenem antibiotic with an exceptionally broad spectrum of antibacterial activity. An evaluation of results of numerous in vitro studies reveals that imipenem effectively inhibited growth of 53 of 55 bacterial species, the mean MIC90 being less than 8 mg/l. The MIC90 for cocci, with the exception of Staphylococcus epidermidis, is in the range of 0.01-3.1 mg/l. The MIC90 for all Enterobacteriaceae is equal to or less than 8 mg/l. Pseudomonas aeruginosa and other non-fermentative gram-negative bacteria are generally susceptible to imipenem, only Pseudomonas maltophilia and Pseudomonas cepacia showing intrinsic resistance. Imipenem is currently the most active drug available against anaerobic bacteria, the MIC usually being below 1 mg/l even for Bacteroides fragilis. Rare bacteria such as Nocardia asteroides, Listeria monocytogenes or fast growing Mycobacterium spp. which cause difficult-to-treat infections are also susceptible to imipenem. Increases in inoculum size have only a minimal effect on activity of the drug. In most species the MBC only slightly exceeded the MIC; however in the case of Streptococcus faecalis the MBC value was many times the MIC value. Synergism has been observed in combinations of imipenem with aminoglycosides, and antagonism in combinations with other beta-lactam antibiotics against Pseudomonas aeruginosa and Serratia marcescens. Imipenem is stable in the presence of the common chromosomal and plasmid-mediated enzymes. Induction of inactivating enzymes was observed in staphylococci, Pseudomonas aeruginosa and Serratia marcescens.

Changing patterns of resistance to new beta-lactam antibiotics. In vitro efficacy of cefoperazone against bacterial pathogens

No evidence for significant increase in resistance to cefoperazone was detected in susceptibility test surveillance programs or in the literature through 1983, but rare endemic resistance to cefoperazone and some other newer beta-lactams was found. Medical centers contemplating the use of a third-generation drug for cost-containment should be aware of the susceptibility of isolates in their hospitals, and the drug's ability to withstand beta-lactamase hydrolysis by local pathogens. The possible dangers of inducible cephalosporins in certain Enterobacteriaceae and strains of Pseudomonas aeruginosa are discussed in the light of the physical and chemical characteristics of the newer antimicrobial agents. Criteria for judging the values of investigational beta-lactams are presented. These focus on the interaction of antimicrobial agents with host defense mechanisms and circulating blood elements.

Susceptibility profiles of potential aerobic and anaerobic pathogens isolated from hysterectomy patients

A total of 1140 aerobic and anaerobic isolates were recovered from cultures of specimens from the reproductive tracts of 435 uninfected patients who underwent elective hysterectomy. Standard minimum inhibitory concentration susceptibility studies were performed on these isolates to 13 newer penicillins, cephalosporins, and some traditional antimicrobial agents. These data were generated to evaluate the in vitro efficacy of these antibiotics for potential use in prophylaxis or as a single agent for treatment of polymicrobial infections of the female pelvis. The minimum inhibitory concentration data for each antibiotic against 16 genera of aerobic and nine genera of anaerobic bacteria were determined and were used to compare the in vitro antimicrobial activity of newer antibiotics to that of the more traditional antibiotics. Of the antimicrobial agents tested, piperacillin had the highest in vitro activity against these isolates of any antibiotic tested.

Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use

Moxalactam (latamoxef) is a new synthetic oxa-beta-lactam antibiotic administered intravenously or intramuscularly. It has a broad spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria, is particularly active against Enterobacteriaceae and is resistant to hydrolysis by beta-lactamases. Moxalactam has moderate activity against Pseudomonas aeruginosa, but on the basis of present evidence can not be recommended as sole antibiotic treatment of known or suspected pseudomonal infections. Like the related compounds, the cephalosporins, moxalactam is effective in the treatment of complicated urinary tract infections and lower respiratory tract infections caused by Gram-negative bacilli. As moxalactam is also active against Bacteroides fragilis it has considerable potential in the treatment of intra-abdominal infections in patients with normal immunological mechanisms, as well as in immunocompromised patients, when used alone or in combination with other antibiotics. Likewise, its ready penetration into the diseased central nervous system, its high level of activity against Gram-negative bacilli, and the lack of necessity to monitor drug plasma concentrations, indicate its potential value in the treatment of neonatal Gram-negative bacillary meningitis. Further clinical experience is needed before it can be determined whether moxalactam alone can be used in the treatment of conditions for which the aminoglycosides are drugs of choice, but if established as equally effective, moxalactam has the advantage of being devoid of nephrotoxicity. Bleeding is a potentially serious problem, however, particularly in the elderly, malnourished and in the presence of renal impairment.